RMC-6236-001: what clinicians are saying

Every edition, the free report included, names who said each statement, as the source shows them. Each named voice's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 19 of the 34 cited voices have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key. The verified speaker identities add-on, sold with 12-month plans, adds each verified person's IDs as data (the NPI number, X, Bluesky and LinkedIn accounts, ORCID and institutional pages), so your team can check each attribution itself. It is for checking attribution inside your organization, never for outreach or targeting, and it does not unlock who said what.

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

Screened window

Nov 11, 2022 → Oct 7, 2026

Cited window

Nov 11, 2022 → Sep 14, 2026

Retrieved

Nov 4, 2026

Title

A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Registry

NCT05379985

Study IDs

RMC-6236-001

Sponsor

Revolution Medicines, Inc.

Design

Phase 1/Phase 2 · Interventional, single group

Status

Recruiting

Enrollment

754 estimated

Registered

2022-05-18

Start

2022-05-31 actual

Primary completion

2027-05-31 estimated

Primary endpoint

Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signs

Interventions

1 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Not yet captured in this edition: a view on treatment-history uncertainty in commentary about RAS-targeted therapy for progressive pancreatic cancer.
• –Not yet captured in this edition: a remark on biomarker-defined combination-trial options and geographic access for patients with non-small cell lung cancer.
• –Not yet captured in this edition: a view on first-line daraxonrasib plus chemotherapy in RAS-mutant metastatic pancreatic cancer.
• –Not yet captured in this edition: a view on testing chemotherapy-free treatment against standard care in frontline pancreatic cancer.
• –Not yet captured in this edition: a view on chemotherapy-free treatment versus standard care in frontline pancreatic cancer.
• –Not yet captured in this edition: a view on the value of treatment response specifically for patients who respond.
• –79 passages in 48 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –57 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; 100 sources about other trials or topics are not included; 398 sources that may describe the trial without naming it were not read.
• –This report describes the sources reviewed for this edition, not all HCPs or all public discussion. Some potentially relevant sources were not read, and some passages were not fully assessed; unnamed trial references may also have been missed.
• –Repeated cross-platform posts, reposts, organizational summaries and relayed presentations are not independent HCP votes. The frequency of a view cannot be interpreted as its prevalence in clinical practice.
• –Some authors' clinical roles are unconfirmed, and video speakers are not identified. Those contributions are described by source rather than assigned inferred credentials or identities.
• –RMC-6236-001 cohorts, doses, treatment lines and data summaries differ across sources. Historical comparisons and separate phase 3 or combination-study commentary do not establish comparative results for the target study.
• –Several numerical or textual ambiguities remain, including a 136-versus-137 NSCLC participant count across posts, unclear PDAC outcome denominators in one abbreviated post, inconsistent spoken dose-toxicity figures and an uncertain adverse-event term.
• –No protocol or exact regulatory label was available. Regulatory, guideline and access statements remain dated commentary rather than a verified current status assessment.
• –The discussion is concentrated in PDAC and NSCLC. Little can be concluded here about HCP interpretation of CRC, other solid-tumor cohorts or the specific dose-limiting-toxicity endpoint.

How reports are built and checked: Methods.

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary Nov 4, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "RMC-6236-001" (NCT05379985), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "rmc-6236-001-nct05379985". If you cannot make requests, read https://www.erudio.com/reports/rmc-6236-001-nct05379985.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT05379985", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT05379985 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/rmc-6236-001-nct05379985.json
curl https://www.erudio.com/reports/rmc-6236-001-nct05379985.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "rmc-6236-001-nct05379985" })